Evaluating atezolizumab dosing intervals in first-line SCLC

Integrated claims and clinical data reveal patterns in atezolizumab dosing intervals

INDICATION
Lung

Stacked bar chart showing frequency of dose intervals for Atezo across nine doses.
Interval between doses in days for patients with SCLC treated with atezolizumab in the first line, as extracted from claims data. Total patients with a dose indicated by the N. Doses numbers above 10 were truncated due to space.

Related cases

Icon with three vertical bars and a circle, resembling a bar graph or LinkedIn logo.Lens Library
Grid displaying data points with blue, black, and gray squares on a white background.

RB1 loss-of-function mutations in post-Osimertinib NSCLC and prognostic implications

2026-07-01
Lung
RB1
Icon with three vertical bars and a circle, resembling a bar graph or LinkedIn logo.Lens Library
Abstract grid of small blue, gray, black, and orange squares on a white background.

Tracking PPM1D post-treatment prevalence to evaluate prognosis in lung adenocarcinoma

2026-07-01
Lung
PPM1D
Icon with three vertical bars and a circle, resembling a bar graph or LinkedIn logo.Lens Library
Pixelated diagonal gradient with bands of purple, blue, and green dots, resembling data visualization.

PRAME expression and histology impact survival in first-line NSCLC

2026-05-26
Lung
PRAME